Physical therapy provides modest improvement for chronic low back pain
Kinesio taping offers only modest relief for musculoskeletal disorders
Scoliosis treatment: Can it help as you get older?
What factors speed up aging?
New resistance training guidance may simplify your workout
The problem with "classic" Lyme disease symptoms
Healthier plant-based diet tied to lower risk of dementia
Is MRI contrast dye safe?
Are those body aches a sign of gallstones?
Staying active throughout middle age may lower women's risk of dying early
Adam S. Cheifetz, MD
Contributor
Dr. Adam Cheifetz is director of the center for inflammatory bowel disease and medical director of infusion services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School. He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. He is involved in multiple research projects relating to IBD, and has published over 200 articles and chapters on the subject.
His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.
Physical therapy provides modest improvement for chronic low back pain
Kinesio taping offers only modest relief for musculoskeletal disorders
Scoliosis treatment: Can it help as you get older?
What factors speed up aging?
New resistance training guidance may simplify your workout
The problem with "classic" Lyme disease symptoms
Healthier plant-based diet tied to lower risk of dementia
Is MRI contrast dye safe?
Are those body aches a sign of gallstones?
Staying active throughout middle age may lower women's risk of dying early
